India should have been granted an out-of-cycle review from the Office of the U.S. Trade Representative over growing concerns about the country's diminishing protections for patented drugs, said Jay Taylor, PhRMA's vice president. "Over the past year, the Government of India has issued several intellectual property decisions that have disproportionately impacted U.S. biopharmaceutical companies and a number of other innovative sectors," Taylor said. PhRMA also was disappointed that Canada was moved to this year's Watch List from the Priority Watch List in the Special 301 trade report despite a lack of progress in policies, Taylor said.

Related Summaries